Strong growth masked by cost pressure, TICMPL execution risk
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Prior guidance (double-digit growth, margin recovery) intact; FY27 EV breakeven targets on track but volume/cost misses narrowing margin of safety.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
TI delivered strong consolidated revenue growth (33% YoY) and PAT growth (39%), with core segments healthy. However, near-term margin recovery is uncertain—commodity and FX headwinds are acute, and TICMPL (high-capex EV venture) volumes are below management's own comfort level, with profitability still 2-4 quarters away. Stock down 50% from Oct 2024 suggests market skepticism on capital efficiency.
₹7330.3 Cr
Revenue · +32.7% YoY₹420.6 Cr
Reported PAT · +39.2% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Double-digit growth trajectory at consolidated level
MET32.7% YoY revenue growth, 39.2% PAT growth
Medical business growing 20% YoY with profitability
METConfirmed on call; exact Q2 contribution not itemized separately
Cost headwinds will be recovered in next 1-2 quarters
OVERSTATEDQ2 margins compressed (10% OPM vs prior guidance); recovery timing unverified
TICMPL volumes scaling across four businesses
MISSQ2: Truck 311, 3W 2,242, SCV 483, Tractor 50 units; analyst noted 'not happy, should be higher'
TICMPL HCV will be EBITDA breakeven Q4 FY27
UnverifiedBreakeven target stated; not yet achieved; costs 75% above run-rate
Earnings quality
What changed since the last call
Cost pressure intensity
DowngradeCommodity and FX headwinds more acute than prior call implied; recovery pushed to 1-2 quarters vs immediate (i.e., delay in margin normalization).
TICMPL capital requirement
NeutralRs 250 Cr Q3 investment confirmed; total Rs 600-700 Cr annual group capex plan reaffirmed (no change).
EV breakeven timeline
NeutralHCV Q4 FY27, two others Q4 FY28 reaffirmed; no movement vs prior call.
The Q&A
Analysts pressed hard on TICMPL volumes (Vipulkumar: 'should be higher'), profitability lag (Salil Desai: costs 75% above run-rate), and capital allocation (Gnanasundaram: why accumulate cash?). Management held confident but hedged on price increases ('market may not be ready') and blamed external factors (commodity, FX). Credibility strained by acknowledgment of miss.
TICMPL volume scaling — Vipulkumar Shah, Sumangal Investments
AnsweredI am not happy with any of the four numbers. All four should be higher. Competition intensifying but we have 25-26% market share in two, targeting leadership.
TICMPL profitability gap — Salil Desai, Marcellus Investment Managers
PartialCommodity costs, cell prices, rupee weakness drove BOM cost increase. We will take price hikes, reduce costs via BOM optimization, and improve deal realization. Timeline uncertain.
Operating margin stagnation — Gopalakrishnan S, Uthrasuuli Investment
DodgedT1, T2, T3 strategy: core business focus, new initiatives, selective acquisitions. Will achieve double-digit growth and higher margins. TICMPL is a major opportunity. Profitability a matter of time and confidence.
TICMPL breakeven credibility — Rushabh Shah, RBSA Investment Managers
PartialFour businesses at different maturity stages. Scale, BOM cost focus, after-sales support, and new use cases will drive profitability. Two-three tailwinds under way. Timeframe firm but execution-dependent.
Medical profitability — Anupam Gupta, HDFC MF
PartialWill take time to stabilize. Our perspective is higher double-digit teen numbers. Once investments settle and team in place (by Q3), profitability will improve significantly.
Core business capex and cash flow — Gnanasundaram S, Avendus Park
AnsweredTICMPL, medical, CDMO are major investments internally funded. Will deploy cash opportunistically into new ventures if right opportunity appears. Not holding excess; working on capital allocation principles.
International business headroom — Gnanasundaram S, Avendus Park
AnsweredGeopolitical issues prevented growth. Now stabilized at 15% from TI level. Customer contracts running well; no walkouts. Will revisit growth if geopolitical stabilizes.
Guidance
FY27 double-digit growth trajectory at consolidated level
HighQ2 delivered 33% YoY; guidance reaffirmed with T1, T2, T3 strategy focus on core and new ventures.
Higher double-digit EBIT margin improvement, cost recovery in 1-2 quarters
MediumCommodity and FX headwinds to reverse; pricing lag of 1-2 quarters acknowledged; recovery unproven.
Medical business to achieve higher double-digit teen profitability margins
MediumPost-Q3 when team in place; investment phase ongoing; amortization drag Rs 4 Cr/quarter.
Rs 350 Cr (TI) + Rs 100 Cr (Shanthi); total group Rs 600-700 Cr FY27
HighTICMPL dominant consumer (Rs 250 Cr Q3 planned); medical and CDMO incremental.
Risks the call surfaced
TICMPL execution & profitability
HighFour EV businesses underperforming; HCV 311 units Q2, 3W 2,242 units, SCV 483 units. Analyst feedback: 'not happy with any numbers.' Breakeven Q4 FY27 depends on cost absorption and price increases.
Commodity and FX headwinds
HighCell prices, commodity surge, and rupee weakness drove BOM cost increase across all businesses. Recovery timeline 1-2 quarters; market pricing power uncertain. Engineering and metal divisions margin compression evident.
Capital allocation efficiency
HighRs 600-700 Cr annual group capex with TICMPL as dominant sink. External PE partner (Rs 2,250 Cr original investment) has NOT invested further despite planned Rs 250 Cr each in Q3 and beyond. TI funding alone; leverage/cash burn risk.
Customer concentration in emerging segments
MediumMining segment is 40% of truck revenue base. Electrification adoption depends on mining sector growth, charging infrastructure, and battery economics. Fixed-route operators concentrated in select cities (Bengaluru, Delhi, Ahmedabad).
New venture profitability timeline
MediumMedical business growing 20% but profitability deferred; CDMO regulatory approval still ~1 year away. Amortization drag Rs 4 Cr/quarter; sustainable margins (double-digit teen) post-Q3, unproven.
Management
Score 6/10. Transparent on segment numbers and cost pressures; hedged on price increases and breakeven credibility. No forward-looking revenue/margin targets quantified. Defensive when pressed on TICMPL volumes. Prior guidance on double-digit growth (met: 33% delivered), EV breakeven timeline (on track Q4 FY27), and medical 20% growth (confirmed) tracking. Margin recovery timeline extended 1-2 quarters due to cost pressures; not a miss but a delay.
1 · Q3 & Q4 FY27
Cost pass-through to customers; commodity price softening expected
2 · Q4 FY27
TICMPL HCV EBITDA breakeven target
3 · Q1 FY28
TICMPL SCV and 3-wheeler breakeven; medical profitability ramp
Stock down 50% from Oct 2024 suggests market skepticism on capital efficiency.
Informational and educational content only. Not investment advice.